Akari Therapeutics Plc (AKTX) SEC Filings

Akari Therapeutics reported second quarter 2026 results and progress on its oncology pipeline. Research and development expense rose to $2.1 million from $0.7 million a year earlier, reflecting expanded IND-enabling and manufacturing work for lead ADC candidate AKTX-101. General and administrative expense was $2.5 million, unchanged from the prior-year quarter. Net loss widened to $4.8 million from $1.9 million.

Akari reported cash of $7.7 million as of June 30, 2026, up from $5.2 million at year-end 2025, supported by approximately $8.6 million of financing during the quarter, led by long-term strategic investors. The company highlighted preclinical ASCO 2026 data for its PH1 spliceosome-modulating payload, a strategic research collaboration with Whitehawk Therapeutics focused on dual-payload ADCs, and continued IND-enabling activities for AKTX-101 toward a planned Phase 1 trial in mid-2027.

Akari Therapeutics, Plc reported a larger net loss of $19.3 million for the six months ended June 30, 2026, compared with $5.6 million a year earlier. Results include non‑cash impairment charges of $3.7 million on AKTX‑101 IPR&D and $8.4 million on goodwill following declines in market value.

Cash and restricted cash were $7.8 million at June 30, 2026, versus $5.3 million at year-end 2025, after raising $5.2 million net in a May 2026 private placement and $3.0 million from warrant exercises. Shareholders’ equity declined to $18.6 million from $28.3 million.

Management states that existing cash is not sufficient to fund operations for 12 months, raising substantial doubt about Akari’s ability to continue as a going concern. The company entered a $25 million equity line with White Lion, increased authorized ordinary shares, and regained Nasdaq minimum bid compliance via an ADS ratio change. Akari continues to advance lead ADC candidate AKTX‑101 toward IND‑enabling work and entered a strategic preclinical collaboration with Whitehawk Therapeutics.

Akari Therapeutics Plc has a significant shareholder group led by Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc., which report beneficial ownership of 8,000,000,000 Ordinary Shares of Akari Therapeutics.

This holding represents 5.71% of the outstanding class of Ordinary Shares as of June 30, 2026. The reporting persons have shared voting power and shared dispositive power over 8,000,000,000 shares, with no sole voting or dispositive power. The position is held in the ordinary course of business while the reporting person acts as prime broker on behalf of certain clients, who may direct dividends and sale proceeds. The reporting entities state that the filing should not be construed as an admission that they are acting as a group for Section 13(d) or 13(g) purposes.

Akari Therapeutics Plc reports that White Lion Capital LLC has filed as a significant shareholder. White Lion is deemed to beneficially own 7,001,638,477 ordinary shares of Akari, represented by American Depositary Shares, giving it 5.0% of the ordinary shares outstanding as of June 30, 2026.

Each American Depositary Share represents 80,000 ordinary shares. The reported position consists of ordinary shares that may be issued to White Lion under an equity line Common Stock Purchase Agreement, at the determination of Akari. White Lion has sole voting and dispositive power over the reported shares.

Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.

Akari Therapeutics Plc reported that interim CFO Farag Kameel D. received a grant of 1,130 American Depositary Shares representing restricted stock units on July 16, 2026, at a reported price of $11.50 per share. According to the footnote, these ADSs represent RSUs, with each RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share, and the RSUs will vest in full on August 16, 2026. Following this award, the interim CFO directly owns 21,581 ADSs.

Akari Therapeutics Plc director and 10% owner Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026 to acquire 22,474 American Depositary Shares (ADSs). These exercises delivered 5,799 and 15,466 ADSs at $0.0004 per ADS and 1,209 ADSs at $8.00 per ADS. The related pre-funded warrant positions reported were reduced to zero, and the transactions are not designated as occurring under a Rule 10b5-1 trading plan. Each ADS represents 80,000 ordinary shares.

Akari Therapeutics, Plc filed an amended shelf registration to permit the resale by existing holders of up to 5,999,999 American Depositary Shares (ADSs), representing 479,999,920,000 ordinary shares. These ADSs arise from a May 2026 private placement of ADSs, pre-funded warrants and Series H, I and J warrants, plus ADSs issued to the placement agent. The company is not selling any ADSs in this offering and will receive no proceeds from shareholder resales; all sale proceeds go to the selling shareholders. Akari may receive up to approximately $16.5 million only if all related warrants are exercised for cash, which it plans to use for research and development, general and administrative expenses and working capital. As of June 30, 2026, 140,032,769,533 ordinary shares were outstanding, a baseline figure, not the amount being registered. The filing highlights significant potential resale supply and detailed selling shareholder positions subject to 4.99% and 9.99% beneficial ownership limitations on warrant exercises.

Akari Therapeutics, Plc amends its registration statement (File No. 333-297257) solely to file certain exhibits. The amendment attaches amended Articles of Association, deposit agreement documents for American Depositary Shares, forms of warrants (including Pre-Funded, Series H, I, and J), the Securities Purchase Agreement dated May 20, 2026 and its June 23, 2026 amendment, and related legal opinions and consents. The filing is signed by Abizer Gaslightwala as President and CEO on July 8, 2026.